<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04668898</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 17-1846</org_study_id>
    <secondary_id>1U01NS107016-01A1</secondary_id>
    <nct_id>NCT04668898</nct_id>
  </id_info>
  <brief_title>LRRK2, GBA and Other Genetic Biomarkers in Eastern European (Ashkenazi) Jews With and Without Parkinson's Disease</brief_title>
  <acronym>BioPD</acronym>
  <official_title>Dissecting Oligogenic Biomarkers in Ashkenazi Jews With Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single site observational study focused on elucidating the genes and biochemical pathways&#xD;
      involved in causing Parkinson disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This single site study, is enrolling Parkinson disease (PD) patients and their family members&#xD;
      and is limited to participants of Ashkenazi (Eastern European) Jewish descent with GBA and&#xD;
      LRRK2 mutations, or with 3 or more family members with PD. Follow-up will be for three years.&#xD;
      Participants must be in the New York City area yearly and willing to come to Mount Sinai&#xD;
      Downtown for yearly 2 hour study visits which include obtaining personal medical and family&#xD;
      history information, blood, urine and spinal fluid samples, neurological exam and&#xD;
      neuropsychiatric testing. De-identified data and samples will be securely stored at a central&#xD;
      NIH-run repository for access by other researchers. Spinal fluid collection is encouraged but&#xD;
      optional.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 29, 2019</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Elucidate blood-based genetic biomarkers in Parkinson's disease</measure>
    <time_frame>five years</time_frame>
    <description>Discovery and validation of new blood-based genetic biomarkers (both DNA and expression-based) for Parkinson's disease</description>
  </primary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">190</enrollment>
  <condition>Parkinson Disease</condition>
  <condition>LRRK2</condition>
  <condition>GBA Gene Mutation</condition>
  <arm_group>
    <arm_group_label>LRRK2 Parkinson Disease</arm_group_label>
    <description>Individuals with LRRK2-related Parkinson Disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GBA Parkinson Disease</arm_group_label>
    <description>Individuals with GBA-related Parkinson Disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Idiopathic Parkinson Disease</arm_group_label>
    <description>Individuals with Idiopathic (without any known genetic cause) Parkinson Disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LRRK2 non-manifesting carriers</arm_group_label>
    <description>Individuals without Parkinson Disease who have a LRRK2 mutation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GBA non-manifesting carriers</arm_group_label>
    <description>Individuals without Parkinson Disease who have a GBA mutation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy control</arm_group_label>
    <description>Individuals without a personal or family history (1st or 2nd degree) of a neurodegenerative disease</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      The study team will be collecting DNA (ACD tubes), serum, plasma, RNA, peripheral blood&#xD;
      monocytes, and urine. In a select group of patients, the study team will be collecting&#xD;
      cerebrospinal fluid through a lumbar puncture. Samples are deposited in the Parkinson's&#xD;
      Disease Biomarker Program repository.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Parkinson disease patients and their family members who are of Ashkenazi (Eastern European)&#xD;
        Jewish descent who either have a GBA or LRRK2 mutations or who have 3 or more family&#xD;
        members with PD.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Parkinson disease patients and their family members and is limited to participants of&#xD;
             Ashkenazi (Eastern European) Jewish descent with GBA and LRRK2 mutations, or with 3 or&#xD;
             more family members with PD&#xD;
&#xD;
          -  Participants must be local to the New York City area and willing to come to Mount&#xD;
             Sinai Downtown for annual 2 hour study visits which include obtaining personal medical&#xD;
             and family history information, blood, urine and spinal fluid samples, neurological&#xD;
             exam and neuropsychiatric testing. Spinal fluid collection is encouraged but optional.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -Patients who do not have Parkinson disease or family members of Ashkenazi (Eastern&#xD;
        European) Jewish descent who either has a GBA or LRRK2 mutations OR who has 3 or more&#xD;
        family members with PD.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rachel Saunders-Pullman, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laurie Ozelius, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sonya S Elango, MS</last_name>
    <phone>212-844-6053</phone>
    <email>sonya.elango@mountsinai.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Deborah Raymond, MS</last_name>
    <phone>212-844-8713</phone>
    <email>deborah.raymond@mountsinai.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mount Sinai-- Downtown Union Square</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>11104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonya S Elango, MS</last_name>
      <phone>212-844-6053</phone>
      <email>sonya.elango@mountsinai.org</email>
    </contact>
    <contact_backup>
      <last_name>Deborah Raymond, MS</last_name>
    </contact_backup>
    <investigator>
      <last_name>Rachel Saunders-Pullman, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 9, 2020</study_first_submitted>
  <study_first_submitted_qc>December 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2020</study_first_posted>
  <last_update_submitted>December 9, 2020</last_update_submitted>
  <last_update_submitted_qc>December 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Rachel Saunders-Pullman</investigator_full_name>
    <investigator_title>Professor, Neurology</investigator_title>
  </responsible_party>
  <keyword>Parkinson's disease</keyword>
  <keyword>Parkinsonian Disorders</keyword>
  <keyword>LRRK2</keyword>
  <keyword>GBA</keyword>
  <keyword>Movement Disorders</keyword>
  <keyword>Neurodegenerative Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Clinical data deposited in Parkinson Disease Biomarker Program DMR after study visit</ipd_time_frame>
    <ipd_access_criteria>Investigators whose proposed use of the data has been approved by an independent review committee (&quot;learned intermediary&quot;) identified for this purpose. The type of analysis will be for individual participant data meta-analysis. Data are available indefinitely at: https://pdbp-demo.cit.nih.gov/researchers.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

